OSLO, NORWAY – 24 September 2021: Reference is made to the press release on 15 September 2021 from Genetic Analysis AS (“the Company”, XSAT ticker: GEAN) regarding a public placement of 7,700,00 new shares in the Company at a subscription price of NOK 7.80 per share prior to the listing on the Spotlight Stock Market on 1 October 2021.
Bio-Rad Laboratories Inc (“Bio-Rad”) has been allocated 532,050 new shares and 691,665 new warrants in Genetic Analysis AS. After issue and registration of the new shares, Bio-Rad will hold 5,297,205 shares in Genetic Analysis AS, equalling 21.26% of the shares and votes in the Company. In addition, Bio-Rad holds 691,665 warrants.
For more information, please contact:
Eilert Aamodt, CFO